ProterixBio, Inc. will be attending Biotech Showcase™ 2019, to be held January 7-9th at the Hilton San Francisco Union Square. Biotech Showcase™, along with the Digital Medicine and Medtech Showcase, is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and life science executives in one place during the course of one of the industry’s largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.
Michael F. Miller, Ph.D., president and chief executive officer of ProterixBio, will speak at the conference. He will be highlighting ProterixBio’s proprietary molecular assessments to improve care and accelerate therapeutics development for patients with chronic respiratory diseases. ProterixBio’s first product, a COPD stratification test, identifies patients likely to have future acute events that often lead to ER visits and hospitalizations. COPD is the 3rd leading cause of death and contributes $40B of direct health care spending in the U.S. alone. ProterixBio’s test has strong health economics that make it attractive for targeting enrollment in value-based chronic care programs.